Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Remberger, Mats  [Clear All Filters]
2024
B Grønvold L, Ali MMohamed, Myklebust TÅ, Lenartova A, Remberger M, Abrahamsen IWeum, Tjønnfjord GErland, Myhre AEivind, Fløisand Y, Gedde-Dahl T. Allogeneic stem cell transplant recipients surviving at least 2 years without relapse: outcome and risk factors. EJHaem. 2024;5(1):117-124.
2023
Pereira MPinto, Remberger M, Chen C, Gerbitz A, Kim DDong Hwan, Kumar R, Lam W, Law ADatt, Lipton JH, Michelis FV, et al. Choosing between older matched sibling donor and younger matched unrelated donor in allogeneic hematopoietic cell transplantation: comparison of clinical outcomes in acute myeloid leukemia and myelodysplastic syndrome. Transplant Cell Ther. 2023.
Moya TAlfaro, Mattsson J, Remberger M, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Gerbitz A, et al. Influence of conditioning regimen intensity on outcomes post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remission. Eur J Haematol. 2023.
Gerbitz A, Gary R, Aigner M, Moosmann A, Kremer A, Schmid C, Hirschbuehl K, Wagner E, Hauptrock B, Teschner D, et al. Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study. Front Immunol. 2023;14:1251593.
Schain F, Boissin C, Laczik T, Fedeli S, Remberger M, Blennow O, Dykes J, Eich T, Jones C, Mattsson J, et al. Real-world clinical characterization, healthcare resource utilization and productivity loss in chronic graft versus host patients exposed to extracorporeal photopheresis in Sweden. Transfus Apher Sci. 2023:103705.
Fløisand Y, Remberger M, Bigalke I, Josefsen D, Vålerhaugen H, Inderberg EMarit, Olaussen RW, Gjertsen BTore, Goedkoop R, Geiger C, et al. WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy. Leukemia. 2023.
2021
Novitzky-Basso I, Remberger M, Chen C, Ellison C, Pasic I, Lam W, Law A, Gerbitz A, Viswabandya A, Lipton JH, et al. Anti-thymocyte Globulin and Post-Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-A and -B mismatched donors. Eur J Haematol. 2021.
Novitzky-Basso I, Remberger M, Chen C, Pasic I, Lam W, Law A, Gerbitz A, Viswabandya A, Lipton JH, Kim DD, et al. ATG and Post-transplant Cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. Eur J Haematol. 2021.
2020
Cheng G-S, Selwa KE, Hatt C, Ram S, Fortuna AB, Guerriero M, Himelhoch B, McAree D, Hoffman TC, Brisson J, et al. Multicenter Evaluation of Parametric Response Mapping as an Indicator of Bronchiolitis Obliterans Syndrome After Hematopoietic Stem Cell Transplantation. Am J Transplant. 2020.
Legert KGarming, Ringdén O, Remberger M, Törlén J, Mattsson J, Dahllöf G. Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft-versus-host disease prophylaxis. Oral Dis. 2020.
2019
Törlén J, Gaballa A, Remberger M, Mörk L-M, Sundberg B, Mattsson J, Uhlin M. Effect of graft-versus-host disease prophylaxis regimens on T and B cell reconstitution after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.
El-Serafi I, Remberger M, Ringdén O, Törlén J, Sundin M, Björklund A, Winiarski J, Mattsson J. Reduced risk of sinusoidal obstruction syndrome of the liver after Busulfan-Cyclophosphamide conditioning prior to allogeneic hematopoietic stem cell transplantation. Clin Transl Sci. 2019.
Nilsson C, Hulegårdh E, Garelius H, Möllgård L, Brune M, Wahlin A, Lenhoff S, Frödin U, Remberger M, Höglund M, et al. Secondary acute myeloid leukemia and the role of allogeneic stem cell transplantation in a population-based setting. Biol Blood Marrow Transplant. 2019.
2018
Ringdén O, Remberger M, Gustafsson B, Moretti G, Mattsson J, Winiarski J, Sadeghi B. THE OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INHERITED DISEASES IS INFLUENCED BY HLA MATCH, YEAR OF TRANSPLANTATION AND IMMUNIZED FEMALE DONOR. Transplantation. 2018.
2016
Törlén J, Ringdén O, Garming-Legert K, Ljungman P, Winiarski J, Remes K, Itälä-Remes M, Remberger M, Mattsson J. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. Haematologica. 2016.
2014
Legert KGarming, Tsilingaridis G, Remberger M, Ringdén O, Heimdahl A, Yucel-Lindberg T, Dahllöf G. The relationship between oral mucositis and levels of pro-inflammatory cytokines in serum and in gingival crevicular fluid in allogeneic stem cell recipients. Support Care Cancer. 2014.
Blennow O, Fjaertoft G, Winiarski J, Ljungman P, Mattsson J, Remberger M. Varicella zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis - the incidence remains high. Biol Blood Marrow Transplant. 2014.
2013
Machaczka M, Johansson J-E, Remberger M, Hallböök H, Lazarevic VLj, Wahlin BEngelbrekt, Omar H, Wahlin A, Juliusson G, Kimby E, et al. High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse. Med Oncol. 2013;30(4):762.